Cargando…
Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune–Albright Syndrome
Fibrous dysplasia (FD) is a rare, non-inherited bone disease occurring following a somatic gain-of-function R201 missense mutation of the guanine-nucleotide binding protein alpha subunit stimulating activity polypeptide 1 (GNAS) gene. The spectrum of the disease ranges from a single FD lesion to a c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916440/ https://www.ncbi.nlm.nih.gov/pubmed/36768871 http://dx.doi.org/10.3390/ijms24032550 |
_version_ | 1784886126588198912 |
---|---|
author | Tucker-Bartley, Anthony Selen, Daryl J. Golden, Emma van Gool, Raquel Ebb, David Mannstadt, Michael Upadhyay, Jaymin |
author_facet | Tucker-Bartley, Anthony Selen, Daryl J. Golden, Emma van Gool, Raquel Ebb, David Mannstadt, Michael Upadhyay, Jaymin |
author_sort | Tucker-Bartley, Anthony |
collection | PubMed |
description | Fibrous dysplasia (FD) is a rare, non-inherited bone disease occurring following a somatic gain-of-function R201 missense mutation of the guanine-nucleotide binding protein alpha subunit stimulating activity polypeptide 1 (GNAS) gene. The spectrum of the disease ranges from a single FD lesion to a combination with extraskeletal features; an amalgamation with café-au-lait skin hyperpigmentation, precocious puberty, and other endocrinopathies defines McCune–Albright Syndrome (MAS). Pain in FD/MAS represents one of the most prominent aspects of the disease and one of the most challenging to treat—an outcome driven by (i) the heterogeneous nature of FD/MAS, (ii) the variable presentation of pain phenotypes (i.e., craniofacial vs. musculoskeletal pain), (iii) a lack of studies probing pain mechanisms, and (iv) a lack of rigorously validated analgesic strategies in FD/MAS. At present, a range of pharmacotherapies are prescribed to patients with FD/MAS to mitigate skeletal disease activity, as well as pain. We analyze evidence guiding the current use of bisphosphonates, denosumab, and other therapies in FD/MAS, and also discuss the potential underlying pharmacological mechanisms by which pain relief may be achieved. Furthermore, we highlight the range of presentation of pain in individual cases of FD/MAS to further describe the difficulties associated with employing effective pain treatment in FD/MAS. Potential next steps toward identifying and validating effective pain treatments in FD/MAS are discussed, such as employing randomized control trials and probing new pain pathways in this rare bone disease. |
format | Online Article Text |
id | pubmed-9916440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99164402023-02-11 Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune–Albright Syndrome Tucker-Bartley, Anthony Selen, Daryl J. Golden, Emma van Gool, Raquel Ebb, David Mannstadt, Michael Upadhyay, Jaymin Int J Mol Sci Review Fibrous dysplasia (FD) is a rare, non-inherited bone disease occurring following a somatic gain-of-function R201 missense mutation of the guanine-nucleotide binding protein alpha subunit stimulating activity polypeptide 1 (GNAS) gene. The spectrum of the disease ranges from a single FD lesion to a combination with extraskeletal features; an amalgamation with café-au-lait skin hyperpigmentation, precocious puberty, and other endocrinopathies defines McCune–Albright Syndrome (MAS). Pain in FD/MAS represents one of the most prominent aspects of the disease and one of the most challenging to treat—an outcome driven by (i) the heterogeneous nature of FD/MAS, (ii) the variable presentation of pain phenotypes (i.e., craniofacial vs. musculoskeletal pain), (iii) a lack of studies probing pain mechanisms, and (iv) a lack of rigorously validated analgesic strategies in FD/MAS. At present, a range of pharmacotherapies are prescribed to patients with FD/MAS to mitigate skeletal disease activity, as well as pain. We analyze evidence guiding the current use of bisphosphonates, denosumab, and other therapies in FD/MAS, and also discuss the potential underlying pharmacological mechanisms by which pain relief may be achieved. Furthermore, we highlight the range of presentation of pain in individual cases of FD/MAS to further describe the difficulties associated with employing effective pain treatment in FD/MAS. Potential next steps toward identifying and validating effective pain treatments in FD/MAS are discussed, such as employing randomized control trials and probing new pain pathways in this rare bone disease. MDPI 2023-01-29 /pmc/articles/PMC9916440/ /pubmed/36768871 http://dx.doi.org/10.3390/ijms24032550 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tucker-Bartley, Anthony Selen, Daryl J. Golden, Emma van Gool, Raquel Ebb, David Mannstadt, Michael Upadhyay, Jaymin Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune–Albright Syndrome |
title | Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune–Albright Syndrome |
title_full | Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune–Albright Syndrome |
title_fullStr | Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune–Albright Syndrome |
title_full_unstemmed | Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune–Albright Syndrome |
title_short | Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune–Albright Syndrome |
title_sort | pharmacological interventions targeting pain in fibrous dysplasia/mccune–albright syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916440/ https://www.ncbi.nlm.nih.gov/pubmed/36768871 http://dx.doi.org/10.3390/ijms24032550 |
work_keys_str_mv | AT tuckerbartleyanthony pharmacologicalinterventionstargetingpaininfibrousdysplasiamccunealbrightsyndrome AT selendarylj pharmacologicalinterventionstargetingpaininfibrousdysplasiamccunealbrightsyndrome AT goldenemma pharmacologicalinterventionstargetingpaininfibrousdysplasiamccunealbrightsyndrome AT vangoolraquel pharmacologicalinterventionstargetingpaininfibrousdysplasiamccunealbrightsyndrome AT ebbdavid pharmacologicalinterventionstargetingpaininfibrousdysplasiamccunealbrightsyndrome AT mannstadtmichael pharmacologicalinterventionstargetingpaininfibrousdysplasiamccunealbrightsyndrome AT upadhyayjaymin pharmacologicalinterventionstargetingpaininfibrousdysplasiamccunealbrightsyndrome |